Cargando…

Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy

Detalles Bibliográficos
Autores principales:	Suozzi, Kathleen C., Stahl, Maximilian, Ko, Christine J., Chiang, Anne, Gettinger, Scott N., Siegel, Mark D., Bunick, Christopher G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949498/ https://www.ncbi.nlm.nih.gov/pubmed/27486590 http://dx.doi.org/10.1016/j.jdcr.2016.05.002

Ejemplares similares

Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature
por: Reuss, Joshua E., et al.
Publicado: (2016)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients
por: Reichert, Constance, et al.
Publicado: (2023)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022)

Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies
por: Gunawan, Florence, et al.
Publicado: (2018)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies
por: Zhang, Jason, et al.
Publicado: (2019)

Ipilimumab/nivolumab: Immune-related pneumonitis: 2 case reports
Publicado: (2020)

Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis
por: Brastianos, Priscilla K., et al.
Publicado: (2021)

Early Response Assessment in Advanced Stage Melanoma Treated with Combination Ipilimumab/Nivolumab
por: Ma, Vincent T., et al.
Publicado: (2022)

Lung brain metastasis pseudoprogression after nivolumab and ipilimumab combination treatment
por: Melian, Marcos, et al.
Publicado: (2018)

Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors
por: Sanghavi, Kinjal, et al.
Publicado: (2019)

Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma
por: Danno, Tetsuya, et al.
Publicado: (2021)

The best dosage of nivolumab plus ipilimumab combination for melanoma brain metastases
por: Fukumoto, Takeshi, et al.
Publicado: (2022)

A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
por: Lai, Gillianne G.Y., et al.
Publicado: (2022)

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
por: Zhou, Shi, et al.
Publicado: (2019)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
por: Nishimura, Yoshito, et al.
Publicado: (2018)

Ipilimumab/nivolumab: Diffuse pneumonitis: case report
Publicado: (2020)

Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma
por: Towner, Mary, et al.
Publicado: (2022)

SUN-414 Immune Related Adverse Events: Isolated ACTH Deficiency with Nivolumab/Ipilimumab Combination Therapy
por: Magdaleno, Angela, et al.
Publicado: (2019)

Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials
por: Kooshkaki, Omid, et al.
Publicado: (2020)

Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients
por: Stoff, Ronen, et al.
Publicado: (2022)

Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report
por: Guercio, Brendan John, et al.
Publicado: (2021)

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
por: Vauchier, Charles, et al.
Publicado: (2022)

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
por: Marchetti, Paolo, et al.
Publicado: (2020)

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
por: Shitara, Kohei, et al.
Publicado: (2022)

Ipilimumab/nivolumab/tozinameran: Various toxicities: case report
Publicado: (2022)

The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis
por: Chen, Jingjie, et al.
Publicado: (2020)

Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: A retrospective monocentric toxicity analysis
por: Bodensohn, Raphael, et al.
Publicado: (2023)

Paraneoplastic hyperleucocytosis in a melanoma patient after initiation of ipilimumab and nivolumab combination therapy
por: Gambichler, Thilo, et al.
Publicado: (2018)

Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date
por: Remon, Jordi, et al.
Publicado: (2019)

Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab
por: Seyed Jafari, S. Morteza, et al.
Publicado: (2020)

Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
por: Yoshida, Saaya, et al.
Publicado: (2019)

Photosensitive Dermatitis Induced by Nivolumab/Ipilimumab Combination Therapy in a Patient with Malignant Melanoma
por: SAKAGUCHI, Yuri, et al.
Publicado: (2020)

Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
por: Wong, Jeffrey Sum Lung, et al.
Publicado: (2021)

A Case of Immune-Mediated Pneumonitis Associated With Dual Nivolumab and Ipilimumab Immunotherapy Treatment
por: Al-Saghir, Tala, et al.
Publicado: (2023)

Can we do without chemotherapy? A perspective on the combinations nivolumab-chemotherapy and nivolumab–ipilimumab in metastatic gastric and esophageal cancer
por: Derks, Sarah, et al.
Publicado: (2022)

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma
por: Gupta, Mehul, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m5hca2bjsn01davuskfpilol68